文献速递肝病

慢性肝病患者感染SARS-CoV-2后的结局:一项国际登记研究

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
PubMed 文献 · J Hepatol · 2020-10-06

该国际登记研究收集745例慢性肝病合并SARS-CoV-2患者(386例肝硬化、359例无肝硬化),并与620例非慢性肝病患者比较。肝硬化患者死亡率为32%,无肝硬化为8%(p<0.001);死亡率随Child-Pugh分级升高(A级19%、B级35%、C级51%)。基线肝病分期和酒精相关肝病是COVID-19死亡的独立危险因素。

要点

  • 肝硬化患者COVID-19死亡率32%,显著高于无肝硬化者的8%(p<0.001)。
  • 死亡率随Child-Pugh分级递增:A级19%、B级35%、C级51%。
  • 基线肝病分期和酒精相关肝病是COVID-19死亡的独立危险因素。

核心结论

  • 在迄今最大的此类队列中,基线肝病分期和酒精相关肝病是COVID-19死亡的独立危险因素。
  • 这些数据对COVID-19大流行期间全球慢性肝病患者的风险分层具有重要意义。

研究设计与样本

  • 2020年3月25日至7月8日,由2个国际登记处收集745例慢性肝病合并SARS-CoV-2患者的数据,其中386例有肝硬化、359例无肝硬化。
  • 将上述数据与来自英国医院网络的非慢性肝病SARS-CoV-2患者(n=620)数据进行比较。

主要发现

  • 肝硬化患者死亡率为32%,无肝硬化患者为8%(p<0.001)。
  • 肝硬化患者死亡率随Child-Pugh分级升高:A级19%、B级35%、C级51%;主要死因为呼吸衰竭(71%)。
  • 调整基线特征后,总慢性肝病队列中与死亡相关的因素包括年龄(OR 1.02;1.01-1.04)、Child-Pugh A级肝硬化(OR 1.90;1.03-3.52)、B级(OR 4.14;2.4-7.65)、C级(OR 9.32;4.80-18.08)和酒精相关肝病(OR 1.79;1.03-3.13)。
  • 与非慢性肝病患者(n=620)相比,倾向性评分匹配分析显示Child-Pugh B级(+20.0% [8.8%-31.3%])和C级(+38.1% [27.1%-49.2%])肝硬化患者死亡率显著增加。
  • 46%的肝硬化患者发生急性肝功能失代偿,其中21%无呼吸道症状;半数肝功能失代偿患者发生慢加急性肝衰竭。

关键数值与推荐

  • 肝硬化患者死亡率为32%,无肝硬化患者为8%(p<0.001)。
  • 肝硬化患者死亡率按Child-Pugh分级:A级19%、B级35%、C级51%。
  • 调整后与死亡相关的因素:年龄OR 1.02(1.01-1.04);Child-Pugh A级OR 1.90(1.03-3.52)、B级OR 4.14(2.4-7.65)、C级OR 9.32(4.80-18.08);酒精相关肝病OR 1.79(1.03-3.13)。
  • 倾向性评分匹配分析显示,Child-Pugh B级肝硬化患者死亡率较非慢性肝病患者增加20.0%(8.8%-31.3%),C级增加38.1%(27.1%-49.2%)。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic liver disease (CLD) and cirrhosis are associated with immune dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes following SARS-CoV-2 infection. We aimed to determine the impact of COVID-19 on patients with pre-existing liver disease, which currently remains ill-defined. METHODS: Between 25th March and 8th July 2020, data on 745 patients with CLD and SARS-CoV-2 (including 386 with and 359 without cirrhosis) were collected by 2 international registries and compared to data on non-CLD patients with SARS-CoV-2 from a UK hospital network. RESULTS: Mortality was 32% in patients with cirrhosis compared to 8% in those without (p <0.001). Mortality in patients with cirrhosis increased according to Child-Pugh class (A [19%], B [35%], C [51%]) and the main cause of death was from respiratory failure (71%). After adjusting for baseline characteristics, factors associated with death in the total CLD cohort were age (odds ratio [OR] 1.02; 1.01-1.04), Child-Pugh A (OR 1.90; 1.03-3.52), B (OR 4.14; 2.4-7.65), or C (OR 9.32; 4.80-18.08) cirrhosis and alcohol-related liver disease (OR 1.79; 1.03-3.13). Compared to patients without CLD (n = 620), propensity-score-matched analysis revealed significant increases in mortality in those with Child-Pugh B (+20.0% [8.8%-31.3%]) and C (+38.1% [27.1%-49.2%]) cirrhosis. Acute hepatic decompensation occurred in 46% of patients with cirrhosis, of whom 21% had no respiratory symptoms. Half of those with hepatic decompensation had acute-on-chronic liver failure. CONCLUSIONS: In the largest such cohort to date, we demonstrate that baseline liver disease stage and alcohol-related liver disease are independent risk factors for death from COVID-19. These data have important implications for the risk stratification of patients with CLD across the globe during the COVID-19 pandemic. LAY SUMMARY: This international registry study demonstrates that patients with cirrhosis are at increased risk of death from COVID-19. Mortality from COVID-19 was particularly high among patients with more advanced cirrhosis and those with alcohol-related liver disease.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2020. PMID: 33035628. doi:10.1016/j.jhep.2020.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。